Research programme: anti-cancer therapeutics - AriBio
Alternative Names: AR 1011Latest Information Update: 28 Jul 2020
At a glance
- Originator AriBio
- Class Antineoplastics
- Mechanism of Action RNA synthesis inhibitors; Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Colorectal cancer
Most Recent Events
- 28 Jul 2020 No recent reports of development identified for preclinical development in Colorectal-cancer in South Korea (Injection)
- 28 Jul 2020 No recent reports of development identified for research development in Cancer in South Korea
- 01 Jun 2016 Early research in Cancer in South Korea (unspecified route)